Phase 1/2a Study of WVE-007 for Overweight or Obesity
This study is testing a new medication called WVE-007 in adults who are overweight or have obesity. The main goal is to see how safe WVE-007 is and how well your body tolerates it. Researchers will also look at how the medication moves through your body and what effects it has. You may be able to join if you are between 18 and 60 years old and have a Body Mass Index (BMI) between 28 and 35 kg/m2 (or up to 40 kg/m2 for some parts of the study). The study is currently recruiting participants.
- Study design
- This is an interventional study planning to enroll 296 participants. It is a Phase 1/2a study, meaning it's an early-stage trial.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored from Day 1 through the end of the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06842186
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Recruiting
PHASE1Ages 18–60InterventionalTreatmentWave Life Sciences USA, Inc.
~296 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:WVE-007
At a glance
Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The proportion of participants with adverse events
Measured over Day 1 through end of study
Conditions
Where it's being run
6 sites across 4 statesRomania2
United Kingdom2
Maryland1
Moldova1
Study leadership
- Medical Director, MD · STUDY_DIRECTOR · Wave Life Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male and female participants aged 18 to 60 years
BMI 28 to 35 kg/m2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg/ m2 will be allowed.
Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments
Male and female participants aged 18 to 60 years
BMI 35 to 50 kg/m2 (inclusive)
Thyroid stimulating hormone is within normal range at Screening. May be on supplemental thyroid hormone as managed by their prescribing physician and stable within the last 60 days
Have Pre T2D or T2D
Exclusion
History or presence of CV disease, including heart failure (New York Heart Association \[NYHA\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments
History or presence of thyroid disorders
Medical history or diagnosis of causes of liver disease
Use of any siRNA agent in the prior 12 months
Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study
History of significant CV disease in the opinion of the Investigator.
Use of prescription medications (ie, anti-obesity or psychiatric medications) within 14 days or 7 half-lives (whichever is longer) before the first dose of study drug, except for allowed antihypertensive medications and statins.
Taking \>2 antihypertensive medications, or antihypertensive medication dose was changed in the 60 days prior to Screening.
Taking \>1 cholesterol-lowering medication, or cholesterol-lowering medication dose was changed in the 60 days prior to Screening.
Cohorts 1 and 2 (preT2D) only: use of any GLP-1 receptor agonists or dual incretin agonists within the 4 months prior to Screening.
Cohorts 4 and 5 (T2D) only: use of insulin or any medication that directly stimulates pancreatic insulin within the 60 days prior to Screening, including sulfonylureas, meglitinides, GLP-1 receptor agonists, dual incretin agonists, and DPP-4 inhibitors.
Use of any siRNA agent in the prior 12 months.
Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study.
What this trial measures
- The proportion of participants with adverse eventsDay 1 through end of study